- Rating
- 2
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
The paper introduces ProSlide, a hierarchical whole-slide representation model that incorporates molecular knowledge through three stages: protein-feature encoder pretraining, paired WSI-protein supervision, and Prot2Path relational distillation using paired anchors and a bank of paired and standalone protein profiles. The evaluation covers twelve downstream tasks, with component ablations, data-efficiency comparisons, and selected pathologist-annotated qualitative examples.
Critical strengths
- Using standalone molecular profiles to supplement limited paired WSI-protein supervision addresses a real data bottleneck. The staged architecture gives a concrete method for transferring protein-derived relational information to slide features.
- The evaluation spans twelve tasks, and Table 1 reports the highest mean ACC and AUC for ProSlide in each of the three task groups. The paper also includes ablations and pathologist-annotated qualitative examples, although task-level outcomes vary.
Critical weaknesses
- The incremental role of standalone profiles remains incompletely isolated. Stage III uses a paired protein profile to define each teacher query, while standalone profiles appear as similarity references; standalone profiles also support Stage I pretraining. Table 4 does include paired-only and all-profile bank comparisons, but the bank composition and sampling schemes differ, and results are mixed across metrics. It is therefore unclear how much benefit comes specifically from standalone references under matched bank size and training conditions.
- The independent novelty and broad generalization claims need stronger evidence. The approach combines established paired supervision and KL-based relational distillation. Although the task-group averages in Table 1 favor ProSlide, Table S10 includes counterexamples: Task 4 AUC is 76.00 for ProSlide versus 81.96 for GigaPath, and Task 11 accuracy is 53.51 versus 61.45 for PRISM. These do not negate the aggregate gains, but they qualify claims of consistent superiority. Differences in pretrained patch encoders and auxiliary protein data also complicate resource-matched attribution.
Questions for authors
- Holding Stage I pretraining and bank size fixed, what is the effect of replacing standalone references with paired-only, shuffled, or source-restricted profiles?
- With the same patch features, auxiliary data, and compute, does Prot2Path outperform simpler paired alignment and capacity-matched relational distillation?
- Are gains statistically reliable at the patient level for individual tasks, and do they extend beyond the cross-cohort lung-subtyping and external protein-retrieval settings already reported?
3 comments
Responses to W2 and Q2: Contribution and controlled transfer comparisons
W2 & Q2: Shared molecular supervision and the role of Prot2Path.
Our contribution is a framework for acquiring protein knowledge beyond the WSI-paired cohort and transferring it into a slide encoder. PFE learns sample-level molecular representations from paired and standalone profiles; protein-expression supervision initializes the slide encoder; Prot2Path makes standalone molecular states explicit references during transfer. The contribution lies in this use of standalone molecular knowledge, rather than in introducing KL divergence itself.
Both direct alignment and Prot2Path transfer information from the same PFE teacher. Tables 4 and 5 compare them within the ProSlide framework using the same frozen patch-feature backbone. The following scores are averaged equally across the three cancer task groups (%): | Training configuration | Mean balanced ACC | Mean AUROC | | --- | ---: | ---: | | Stage II only | 62.88 | 75.98 | | Stage II + direct alignment | 63.88 | 77.98 | | Stage II + Prot2Path | 64.68 | 77.70 |
Both transfer objectives improve aggregate performance over Stage II, indicating that the benefit of PFE supervision is not confined to one alignment objective. Prot2Path extends paired alignment with soft relational supervision: Table S12 assigns 56.82% of teacher probability to the matched protein reference and distributes the remaining 43.18% across other profiles. This retains a paired molecular anchor while teaching relationships to additional molecular states. We adopt Prot2Path for this explicit participation of standalone references and its higher balanced accuracy across all three cancer groups.
Q2: Relational and simpler-teacher controls.
Table 5 includes paired-bank Soft KL, which uses the same type of relational objective and PFE representation space but restricts references to paired profiles. Prot2Path improves mean ACC and AUROC in each cancer group relative to this control. The frozen reference bank adds molecular targets without introducing another trainable encoder. These within-framework comparisons are more direct evidence about the transfer design than comparisons with separately pretrained slide models.
Table S11 further compares teacher representations under Soft KL. The reported AUROCs (%) are: | Teacher representation | Renal | Breast | Lung | | --- | ---: | ---: | ---: | | Raw Protein | 75.18 | 76.36 | 75.49 | | MLP-AE | 76.01 | 77.49 | 75.95 | | PFE | 76.67 | 78.53 | 77.90 |
PFE obtains higher mean ACC and AUROC than both simpler teachers in all groups, supporting its learned representations as a useful source of supervision beyond the original measurements.
W2 & Q2: Dependence on the pretrained patch encoder.
Table S13 replaces CONCH v1.5 with frozen vision-only UNI2 while keeping the slide aggregation architecture, training data, and evaluation protocol unchanged. Each cell reports balanced ACC / AUROC (%): | Patch encoder | Stage | Renal | Breast | Lung | | --- | --- | ---: | ---: | ---: | | CONCH v1.5 | II | 58.07 / 75.86 | 69.22 / 76.69 | 61.34 / 75.39 | | CONCH v1.5 | III | 60.85 / 76.67 | 70.02 / 78.53 | 63.17 / 77.90 | | UNI2 | II | 59.57 / 75.88 | 69.41 / 78.00 | 61.34 / 76.07 | | UNI2 | III | 60.78 / 76.39 | 70.92 / 78.58 | 63.42 / 78.08 |
Stage III improves both metrics across all three cancer groups with either patch encoder. This extends the observed transfer benefit beyond CONCH v1.5 and provides a controlled comparison within each backbone, using the same auxiliary molecular data.
With UNI2, ProSlide achieves slightly higher mean balanced accuracy and a similar mean AUROC compared with CONCH v1.5. We retain CONCH v1.5 for the main experiments to match the patch encoder used by several key baselines in our evaluation, including FEATHER, TITAN, and CARE (Table S9), thereby reducing differences attributable to the patch-feature backbone.
Responses to W2 and Q3: Statistical evidence and scope of generalization
W2 & Q3: Overall trends and individual-task outcomes.
No evaluated foundation model leads on every task in Table S10. We acknowledge the examples highlighted by the reviewer: ProSlide trails GigaPath in Task 4 AUROC and PRISM in Task 11 balanced accuracy. Sections 4.2 and D.3 discuss endpoint-dependent performance. Our aggregate result is the highest observed mean balanced ACC and AUROC within each of the three selected cancer task groups, rather than leadership on every endpoint.
Figure S1 provides complementary context: ProSlide achieves strong aggregate performance with 2,229 WSIs for slide-level pretraining, and its inference GPU memory usage is lower than TITAN, PRISM, and GigaPath across the evaluated patch counts, and lower than CARE at larger patch counts. These results characterize the combination of predictive performance, slide-level data requirements, and inference memory efficiency.
Q3: Individual-task paired confidence intervals against FEATHER.
To assess the reliability of the gains on individual tasks, we compare ProSlide with FEATHER using paired 95% confidence intervals. Both models use CONCH v1.5 patch features in our evaluation. Differences below are ProSlide minus FEATHER, in percentage points (pp). Task numbers follow Table S10. | Task | Balanced ACC difference [95% CI] | AUROC difference [95% CI] | | --- | --- | --- | | Task 1 | +6.77 [6.55, 6.99] | +2.68 [2.58, 2.78] | | Task 2 | +8.13 [7.96, 8.30] | +2.61 [2.57, 2.65] | | Task 3 | +2.25 [1.97, 2.53] | +9.46 [8.92, 10.00] | | Task 4 | +6.45 [6.06, 6.84] | +8.10 [7.87, 8.33] | | Task 5 | -0.32 [-0.56, -0.08] | +0.77 [0.59, 0.95] | | Task 6 | +4.89 [4.65, 5.13] | +4.53 [4.32, 4.74] | | Task 7 | +7.85 [7.70, 8.00] | +8.83 [8.72, 8.94] | | Task 8 | +0.50 [0.44, 0.56] | +0.81 [0.73, 0.89] | | Task 9 | +3.47 [3.38, 3.56] | +3.08 [2.99, 3.17] | | Task 10 | +0.63 [0.46, 0.80] | -0.11 [-0.25, 0.03] | | Task 11 | -1.77 [-1.84, -1.70] | +2.34 [2.16, 2.52] | | Task 12 | +9.47 [9.15, 9.79] | +7.17 [6.82, 7.52] |
The reported intervals lie entirely above zero on 10 of 12 tasks for balanced ACC and 11 of 12 tasks for AUROC, with both metrics favoring ProSlide on 9 tasks. These positive differences span renal, breast, and lung molecular prediction as well as histological subtyping, extending beyond cross-cohort lung subtyping. Balanced ACC favors FEATHER on Tasks 5 and 11, while the Task 10 AUROC interval includes zero. These individual-task comparisons support the overall advantage over FEATHER while identifying the endpoints where the evidence differs.
W2 & Q3: Evidence beyond lung subtyping and protein retrieval.
Table S13 shows Stage III improvements in both metrics across renal, breast, and lung task groups with both patch encoders. This supports transfer beyond the lung-subtyping examples, although individual endpoints remain variable.
We also add prediction of RNA-derived tumor microenvironment states on three external CPTAC cohorts (Table 3). Patho-Bench labels group gene-expression-derived ESTIMATE scores into low, medium, and high categories reflecting stromal and immune infiltration. Under the same patient splits and logistic-regression protocol, the AUROCs (%) are: | Cohort | Patients | Raw Protein | Protein-BERT | MLP-AE | PFE | | --- | ---: | ---: | ---: | ---: | ---: | | CPTAC-BRCA | 94 | 69.33 | 66.15 | 70.49 | 73.13 | | CPTAC-LSCC | 88 | 71.01 | 80.45 | 78.69 | 82.01 | | CPTAC-LUAD | 73 | 57.61 | 65.99 | 65.60 | 69.83 |
PFE achieves the highest reported mean ACC and AUROC in all three cohorts. This provides biological prediction evidence beyond near-identity retrieval by using independently measured RNA-derived labels. The task evaluates the molecular teacher; the UNI2 and Stage II/III comparisons separately assess transfer to the slide encoder. Together, these experiments broaden the evidence across molecular endpoints and patch encoders while keeping the scope of each evaluation explicit.
Responses to W1 and Q1: Isolating the contribution of standalone profiles